Shifted the ECOsynthesis platform from technical feasibility to supporting preclinical development, targeting a $2 billion addressable market for siRNA production.

Achieved a critical technical milestone by synthesizing 10 grams of commercially relevant siRNA with no quality barriers, validating the platform's sequential synthesis capability.

Surpassed commercial goals by signing three CDMO agreements with Bachem, Nitto Avecia, and Axolabs to address limitations in standard solid-phase chemical processes.

Stabilized the heritage small-molecule biocatalysis business, returning it to healthy profit margins to provide a self-sustaining financial foundation for RNA innovation.

Modernized non-GMP production infrastructure in Redwood City, achieving ISO 9001 certification and passing a major pharmaceutical customer's quality inspection.

Introduced stereochemical control as a new platform feature, potentially offering customers superior therapeutic potency and purity compared to traditional methods.

Projecting 2026 revenue between $72 million and $76 million, with performance expected to be more heavily weighted toward the second half of the year.

Scaling ECOsynthesis production from the current 100-gram scale toward a half-kilogram target by the end of 2026 to meet growing industry demand.

Commencing construction on a new GMP facility in the second half of 2026, with full operational status targeted for late 2027 to enable clinical supply.

Anticipating the signing of at least one major licensing-type deal in 2026, following the successful $38 million technology transfer model established with Merck.

Utilizing cost savings from Q4 2025 restructuring to partially offset capital expenditures for the GMP build-out, maintaining a stable cash burn rate.

Recorded a one-time restructuring charge of $3.4 million in Q4 2025 related to organizational realignment aimed at long-term expense reduction.

Secured $37.8 million in non-dilutive capital via the Merck technology transfer, extending the company's cash runway through 2027.

Identified 14 late-stage clinical programs in the small-molecule pipeline, with two recent positive data readouts expected to drive commercial launch activity.

Maintained stable product gross margins at 64% by optimizing product mix and exiting several low-margin legacy product lines.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management is currently examining biological activity and expects to present substantive data on improved potency at the TIDES U.S. meeting.

Several customers with siRNA assets have already initiated collaborative conversations to explore how this control can improve their specific drug profiles.

The recently announced low 7-figure contract serves as a prototype for moving customers from feasibility studies to preclinical material supply.

Success in this phase is intended to lead to multi-year agreements involving licensing fees, milestone payments, and clinical supply as assets move toward IND submissions.

Management estimates total industry demand could reach 10 to 30 metric tons of oligonucleotide material by 2030, driven by large-indication assets in pharma pipelines.

The ECOsynthesis platform is being positioned as a necessary alternative to current technologies that cannot scale to meet these projected volumes.

Guidance is built on historical buying practices and existing contracts, with management claiming line of sight on a large percentage of the $72M-$76M target.

While the legacy biocatalysis business provides a stable base, the majority of future growth is expected to be driven by the ECOsynthesis services and licensing.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.